ALZAI Health’s shares started trading on the Frankfurt Stock Exchange this week. It’s the fourth announcement in two months about the company getting bigger somehow, whether that’s a new disease category, a potential new partner, or now a new stock exchange.
Shares Now Trade on the Frankfurt Stock Exchange
ALZAI Health Corp. (TSXV: ALZI) (FSE: H2F), a healthcare technology company building AI-driven disease risk identification tools, announced on September 3 that its common shares are now posted for trading on the Frankfurt Stock Exchange under the symbol H2F, according to the company’s release. The TSXV remains ALZAI’s primary listing. A Frankfurt quotation like this one doesn’t raise any capital on its own. What it does is give European retail and institutional investors a venue to trade the stock without going through a Canadian broker.
The Two Months Before It: A License, an MOU, and a Marketing Contract
The Frankfurt listing caps a run of announcements stretching back to mid-July. On July 20, ALZAI secured an exclusive, worldwide, sublicensable license from MOR Research Applications and Yeda Research for AI-driven liver disease risk identification technology, developed at Clalit Health Services and the Weizmann Institute of Science. The license covers cirrhosis and other chronic liver conditions and moves ALZAI beyond its original Alzheimer’s focus. ALZAI owes customary royalties on future commercialization revenue back to the licensors, a real financial obligation attached to a technology the company hasn’t yet validated or commercialized on its own.
On August 11, ALZAI signed a memorandum of understanding with Linus Health, an AI-driven brain health company, to explore combining ALZAI’s blood-test-based risk models with Linus Health’s cognitive diagnostic tools. The release is explicit that the MOU is non-binding. Six days later, on August 17, ALZAI entered a paid services agreement with Euro Digital Media, a London-based marketing firm, to run market awareness and digital marketing on the company’s behalf. The release doesn’t disclose what ALZAI is paying for it.
What ALZAI Actually Has Validated
Underneath the run of announcements sits one product with real validation data behind it. ALZAI’s Alzheimer’s risk-stratification models were tested against a licensed dataset covering more than 1.1 million U.S. patients, and the company reported performance comparable to an earlier validation run on Israeli healthcare data. That’s the technology ALZAI actually has evidence for. The liver disease license is newly acquired IP without a published validation study yet, and the Linus Health collaboration is still at the exploratory, non-binding stage.
The Numbers
ALZAI had 64,147,682 common shares outstanding following its IPO closing, with roughly 23.5 million of those held by directors, officers, and certain shareholders under escrow restrictions. At a recent share price around $0.40 to $0.45 Canadian, that puts the market capitalization somewhere in the $26 million to $29 million range, a nano-cap by any measure. The company’s IPO warrants carry a $0.60 exercise price, and ALZAI can force early exercise if the stock’s 10-day volume-weighted average price hits $0.90, a dilution mechanic worth watching if the stock ever gets there.
What Actually Moves the Story Forward From Here
A Frankfurt listing brings visibility, not commitments. The real tests are still ahead: whether the Linus Health MOU turns into a signed agreement, whether the liver disease technology gets a validation study of its own the way the Alzheimer’s platform did, and whether any of this activity converts into disclosed revenue rather than another announcement about potential future revenue.
Sources
- ALZAI Health Corp.: ALZAI Health Corp. Posted for Trading On The Frankfurt Stock Exchange, September 3, 2026
- Newsfile Corp.: ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology, July 20, 2026
- Newsfile Corp.: ALZAI and Linus Health Explore AI-Driven Collaborations Aimed at Early Identification of Alzheimer’s Disease Risk and Cognitive Impairment, August 11, 2026
- Newsfile Corp.: Alzai Health Corp. Announces Marketing Services Agreement, August 17, 2026
Editorial Disclosure
This article is based on ALZAI Health Corp.’s September 3, July 20, August 11, and August 17, 2026 releases, distributed via the company’s own newsroom and Newsfile Corp. The security discussed is ALZAI Health Corp. (TSXV: ALZI) (FSE: H2F). aktiego.com has not received any compensation from ALZAI, its management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in this security at the time of publication.
The Linus Health memorandum of understanding referenced in this article is explicitly non-binding, per ALZAI’s own release, and may not result in a definitive agreement or any commercial outcome. The liver disease risk identification technology referenced was licensed by ALZAI in July 2026 and has not, as of this article’s publication, been independently validated or commercialized by the company; ALZAI’s only disclosed large-scale validation data covers its original Alzheimer’s risk model. ALZAI’s marketing services agreement with Euro Digital Media is a paid arrangement; the company’s release does not disclose the fee. Share count, escrow, and warrant terms cited are sourced to ALZAI’s IPO closing disclosure. Market capitalization is calculated from a recent share price and is approximate.
This is a speculative investment carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full
